Health Care & Life Sciences » Pharmaceuticals | AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,293.00
18,123.00
19,024.00
2,515.00
7,579.00
5,409
SG&A Expense
93,405.00
50,624.00
17,525.00
31,878.00
34,317.00
31,433
EBIT
95,887.00
38,720.00
8,068.00
29,393.00
26,738.00
26,024
Unusual Expense
8,117.00
11,729.00
2,042.00
4,751.00
35,813.00
22,886
Non Operating Income/Expense
23.00
66.00
6,689.00
195.00
-
-
Interest Expense
3,127.00
2,388.00
2,307.00
1,949.00
2,373.00
2,191
Pretax Income
107,029.00
52,739.00
15,001.00
26,786.00
64,924.00
5,329
Income Tax
-
-
-
101.00
101.00
-
Consolidated Net Income
107,029.00
52,739.00
15,001.00
26,887.00
65,025.00
5,329
Net Income
107,029.00
52,739.00
15,001.00
26,887.00
65,025.00
5,329
Net Income After Extraordinaries
107,029.00
52,739.00
15,001.00
26,887.00
65,025.00
5,329
Net Income Available to Common
107,029.00
52,739.00
15,001.00
26,887.00
65,025.00
5,329
EPS (Basic)
2.10
1.01
0.27
0.39
0.61
0.19
Basic Shares Outstanding
50,928.00
52,289.00
55,701.00
69,268.00
105,930.00
120,592
EPS (Diluted)
2.10
1.01
0.27
0.39
0.61
0.19
Diluted Shares Outstanding
50,928.00
52,289.00
55,701.00
69,268.00
105,930.00
130,731
EBITDA
92,112.00
32,501.00
1,499.00
29,363.00
26,738.00
26,024
Non-Operating Interest Income
125.00
32.00
21.00
-
-
-

About AVEO Pharmaceuticals

View Profile
Address
One Broadway
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.aveooncology.com
Updated 07/08/2019
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. The company was founded by Ronald A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.